Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing lossWhite Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) -- ...
Challenges include high costs and limited diagnosis, but opportunities for growth lie in gene therapy commercialization, expanded screening, and emerging marketsDublin, April 21, 2026 (GLOBE NEWSWIRE) ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni ...
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of ...
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...
The FDA granted accelerated approval to lunsotogene parvec (Otarmeni) as the first gene therapy for genetic hearing loss, the ...
Formerly known as DB-OTO, lunsotogene parvec is an adeno-associated virus (AAV) vector–based gene therapy administered via a ...
Kratos Defense & Security Solutions (KTOS) is initiated with a Buy rating and a $135 price target, implying 92% upside from ...
Zilliz, the creator of Milvus -- the world's most widely adopted open-source vector database with over 43,000 GitHub stars and more than 10,000 enterprise deployments -- has been recognized as a ...
The FDA has granted an accelerated approval for Otarmeni (lunsotogene parvec-cwha), the first gene therapy to treat patients ...
Richland County Vector Control crews will soon begin spraying for mosquitoes as part of the County's annual effort to protect ...
Turkey’s trajectory is not dependent on the outcome of the Iranian case - it is a function of its desire to claim leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results